# The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

> **NCT00044187** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 130 (—)

## Conditions studied

- Schizophrenia
- Psychotic Disorders
- Bipolar Disorder

## Interventions

- **DRUG:** Sibutramine

## Key facts

- **NCT ID:** NCT00044187
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** 2003-09
- **Target enrollment:** 130 (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044187, "The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00044187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*